RECORD
Detecting adverse high-order drug combinations from individual case safety reports using computational statistics on disproportionality measures
Applications · Submitted 1 Apr 2025
abstract compiled · 2026-09-23 · no language-model review
The authors' main claim Validation on synthetic and FDA Adverse Event Reporting System data demonstrates the method's efficacy in detecting established drugs and drug interactions associated with myopathy-related adverse events.
The compiled record
The paper's own sentences, arranged. Each label is drawn from a closed vocabulary; the number beside it is the probability the classifier gave that label. Numbers in the tables are the authors', checked by code. No sentence in this record was written by a model.
Open the compiled record
The abstract, sentence by sentence
Adverse drug interactions are a critical concern in pharmacovigilance, as both clinical trials and spontaneous reporting systems often lack the breadth to detect complex drug interactions. This study introduces a computational framework for adverse drug interaction detection, leveraging disproportionality analysis on individual case safety reports. By integrating the Anatomical Therapeutic Chemical classification, the framework extends beyond drug interactions to capture hierarchical pharmacological relationships. To address biases inherent in existing disproportionality measures, we employ a hypergeometric risk metric, while a Markov Chain Monte Carlo algorithm provides robust empirical p-value estimation for the risk associated to cocktails. A genetic algorithm further facilitates efficient identification of high-risk drug cocktails. Validation on synthetic and FDA Adverse Event Reporting System data demonstrates the method's efficacy in detecting established drugs and drug interactions associated with myopathy-related adverse events. Implemented as an R package, this framework offers a reproducible, scalable tool for post-market drug safety surveillance.
background contribution method result interpretation main claim
| # | sentence | role | the authors' own work | states the main conclusion | strength |
|---|---|---|---|---|---|
| s0 | Adverse drug interactions are a critical concern in pharmacovigilance, as both clinical trials and spontaneous reporting systems often lack the breadth to detect complex drug interactions. | background 0.92 | 0.05 | 0.03 | asserted 0.98 |
| s1 | This study introduces a computational framework for adverse drug interaction detection, leveraging disproportionality analysis on individual case safety reports. | contribution 0.99 | 0.90 | 0.10 | asserted 1.00 |
| s2 | By integrating the Anatomical Therapeutic Chemical classification, the framework extends beyond drug interactions to capture hierarchical pharmacological relationships. | method 0.74 | 0.81 | 0.04 | asserted 1.00 |
| s3 | To address biases inherent in existing disproportionality measures, we employ a hypergeometric risk metric, while a Markov Chain Monte Carlo algorithm provides robust empirical p-value estimation for the risk associated to cocktails. | method 0.99 | 0.93 | 0.04 | asserted 1.00 |
| s4 | A genetic algorithm further facilitates efficient identification of high-risk drug cocktails. | method 0.99 | 0.82 | 0.04 | asserted 0.98 |
| s5 | Validation on synthetic and FDA Adverse Event Reporting System data demonstrates the method's efficacy in detecting established drugs and drug interactions associated with myopathy-related adverse events. | result 0.98 | 0.94 | 0.57 | asserted 1.00 |
| s6 | Implemented as an R package, this framework offers a reproducible, scalable tool for post-market drug safety surveillance. | contribution 0.82 | 0.81 | 0.13 | asserted 1.00 |
What was examined, and what was not
- arXiv listing abstract v1
- full text
- figures and tables
- references and citing sentences
- relations to other papers
- P abstract
- S sections
- T body sentences
- C citations
- R cross-paper relations
The paper
Original abstract
Adverse drug reactions linked to the intake of drug combinations are a critical concern in pharmacovigilance, particularly as the controlled environment of clinical trials often lacks the scale and diversity to detect rare events involving multiple medications. While spontaneous reporting systems provide the necessary breadth for post-market surveillance, identifying overrepresented drug cocktails within such large-scale data remains a significant computational challenge. This study introduces a computational framework for the detection of drug cocktails associated with adverse events, leveraging disproportionality analysis on individual case safety reports. By integrating the Anatomical Therapeutic Chemical classification, the framework extends beyond individual drugs to capture hierarchical pharmacological relationships, enabling exploration of the space of drug combinations beyond pairwise analysis. To address biases inherent in existing disproportionality measures, we employ a hypergeometric risk metric, while a Markov Chain Monte Carlo algorithm provides robust empirical p-value estimation for the risk associated with cocktails. A genetic algorithm further facilitates efficient identification of high-risk drug cocktails. A post-treatment step based on penalized logistic regression allows distinguishing true pharmacological interactions from combined individual effects for cocktails of any size. Validation on synthetic and FDA Adverse Event Reporting System data demonstrates the method's efficacy in detecting established drugs and drug combinations associated with myopathy-related adverse events. Implemented as an R package, this framework offers a reproducible, scalable tool for post-market drug safety surveillance.
Human review
How the literature uses it
What this paper does with the arXiv papers it cites
What it cites
Uses the method or tool of 1 paper
-
To do so, drug cocktails are embedded into a two-dimensional space using the UMAP algorithm [ref] , which aims to preserve similarity in the latent space.
UMAP: Uniform Manifold Approximation and Projection for Dimension Reduction · Output clustering · 1.00
Discussion
Know something about this paper? Leave a comment, or highlight any passage above to comment on it.